REG - Arecor Therapeutics - Arecor partnership with biopharmaceutical company

Arecor TherapeuticsAnnouncement

12/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250312:nRSL2596Aa&default-theme=true

RNS Number : 2596A  Arecor Therapeutics PLC  12 March 2025

Arecor Therapeutics plc

("Arecor" or the "Company")

 

ARECOR ESTABLISHES PARTNERSHIP WITH BIOPHARMACEUTICAL COMPANY TO DEVELOP NOVEL
FORMULATION OF PEPTIDE THERAPY

 

-      Partner to fund development work with option to acquire rights to
proprietary formulation under Arecor's technology licensing model

 

Cambridge, UK, 12 March 2025: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces a formulation development collaboration with a
clinical-stage biopharmaceutical company developing peptide therapies. The
partnership aims to develop a differentiated formulation of the partner's
peptide therapy using Arecor's proprietary formulation technology platform,
Arestat™. The collaboration reinforces Arecor's expertise developing novel
formulations of peptide therapeutics.

 

Under the terms of the agreement, the partner will fund Arecor's development
activities with the option to license rights to the new proprietary
formulation and associated intellectual property to further develop and
commercialise the product.

 

Arecor has an excellent track record developing challenging therapeutic
peptide product profiles using its Arestat™ technology. Within the Company's
broader product portfolio, Arecor continues to progress the potential of its
Arestat™ platform to enable oral peptide delivery, through its initial
oral glucagon-like peptide-1 (GLP-1) receptor agonist programme.

 

The global peptide therapeutics market is projected to reach more than $100
billion by 2034 growing at a CAGR of 10.8% (1), driven by peptide
therapeutics' strong efficacy and selectivity towards different receptors on
target cells, the rise of endocrine and metabolic diseases, and technological
advancements in the field.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "Peptides are an
increasingly important class of therapeutics to treat a wide range of chronic
conditions. Arecor has significant expertise in developing novel formulations
of therapeutic peptides to address unmet patient needs in this large and
growing market. This collaboration further validates our leadership in this
field."

 

-ENDS-

 

References

1.    Future Market Insights: Peptide Therapeutics Market Outlook from 2024
to 2034
(https://www.globenewswire.com/news-release/2024/12/26/3001949/0/en/Global-Peptide-Therapeutics-Market-to-Skyrocket-Estimated-Growth-at-a-CAGR-of-10-8-to-Reach-USD-117-4-Billion-by-2034-FMI.html)

 

For more information, please contact:

 

 Arecor Therapeutics plc                                       www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                      Tel: +44 (0) 1223 426060

                                                               Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Interim Chief Financial Officer                  Tel: +44 (0) 1223 426060

                                                               Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Joint Broker)
 Phil Davies, Sam Butcher                                      Tel: +44 (0) 20 7496 3000

 WG Partners LLP (Joint Broker)
 Nigel Barnes, Satheesh Nadarajah                              Tel: +44 (0) 20 3705 9321

 David Wilson, Claes Spang

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville                   Tel: +44 (0) 20 3709 5700

                                                               Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUPPWUPAGMG